New Guide Helps Obese People with Cancer Understand Optimal Weight-Based Chemotherapy Dosing
The American Society of Clinical Oncology has released recommendations to help obese people living with cancer understand and discuss with their doctors the appropriate dosing of chemotherapy for their body weight.
ASCO’s clinical guideline recommends that physicians use an obese person’s actual body weight, rather than an ideal body weight or other estimate, to calculate the appropriate dose of nearly all chemotherapy drugs. Research shows that people with cancer who are obese are more likely to die from cancer than those who are not obese. This may partly reflect the fact that as many as 40 percent of obese people receive limited chemotherapy doses that are not based on actual body weight, most likely due to concerns about side effects and long-standing practice patterns. ASCO’s guideline addresses these concerns, pointing to clear evidence that weight-based dosing maximizes the effectiveness of treatment for obese people without raising the risk of side effects.
To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) developed evidence-based recommendations on giving doses of chemotherapy that are based on a patient’s actual weight.
The new guideline provides background information on the recommendations, explains what those recommendations mean, and suggests questions people can ask their doctors about receiving their best treatment. The questions include:
- Have you given me a dose based on my actual weight, or a standard dose?
- Will you monitor my side effects and decrease my dose if I have side effects?
- Will you return to the original dose after my side effects go away?
♦ ♦ ♦ ♦ ♦